Rationale and design of the RESOLVE trial: Lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease

BMC Nephrology

Volumn 13, Issue 1, 2012, Pages

  Gevers, Tom J G ^a   Chrispijn, Melissa ^a   Wetzels, Jack F M ^a   Drenth, Joost P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ADPKD; Lanreotide; Polycystic liver disease; Urinary biomarkers

Indexed keywords

ALPHA 1 MICROGLOBULIN; ANGIOPEPTIN; FATTY ACID BINDING PROTEIN; FIBROBLAST GROWTH FACTOR 23; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN KIM 1; UNCLASSIFIED DRUG;

ABNORMAL FECES COMPOSITION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATTY FECES; FEMALE; HUMAN; KIDNEY MASS; KIDNEY POLYCYSTIC DISEASE; LIVER POLYCYSTIC DISEASE; LIVER WEIGHT; LOOSE FECES; MALE; PALE FECES; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACUTE-PHASE PROTEINS; ADOLESCENT; ADULT; AGED; ALPHA-GLOBULINS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CHEMOKINE CCL2; CYSTS; FATTY ACID-BINDING PROTEINS; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; LINEAR MODELS; LIPOCALINS; LIVER; LIVER DISEASES; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; ORGAN SIZE; PEPTIDES, CYCLIC; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROTO-ONCOGENE PROTEINS; RECEPTORS, VIRUS; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; SOMATOSTATIN; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84859187999     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-13-17     Document Type: Article

References (25)

1. Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families. Dalgaard OZ, Acta Med Scand Suppl 1957 328 1 255 13469269
2. Autosomal dominant polycystic kidney disease. Torres VE, Harris PC, Pirson Y, Lancet 2007 369 1287 301 10.1016/S0140-6736(07)60601-1 17434405 (Pubitemid 46552051)
3. Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: dichotomy of a spectrum. Gulick JJM, Gevers TJ, van Keimpema L, Drenth JP, Neth J Med
4. Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Gabow PA, Johnson AM, Kaehny WD, Manco-Johnson ML, Duley IT, Everson GT, Hepatology 1990 11 1033 7 10.1002/hep.1840110619 2365280 (Pubitemid 20221041)
5. Volume progression in polycystic kidney disease. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, et al. N Engl J Med 2006 354 2122 30 10.1056/NEJMoa054341 16707749 (Pubitemid 43736612)
6. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, et al. Clin J Am Soc Nephrol 2010 5 783 9 10.2215/CJN.05380709 20185596
7. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, et al. J Am Soc Nephrol 2010 21 1052 61 10.1681/ASN.2009121291 20431041
8. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, et al. Gastroenterology 2009 137 1661 8 10.1053/j.gastro.2009.07.052 19646443
9. Polycystic disease of the liver. Everson GT, Taylor MR, Doctor RB, Hepatology 2004 40 774 82 15382167 (Pubitemid 39288107)
10. Natural history of autosomal dominant polycystic kidney disease. Fick GM, Gabow PA, Annu Rev Med 1994 45 23 9 10.1146/annurev.med.45.1.23 8198379 (Pubitemid 24158142)
11. Medical and surgical treatment options for polycystic liver disease. Drenth JP, Chrispijn M, Nagorney DM, Kamath PS, Torres VE, Hepatology 2010 52 2223 30 10.1002/hep.24036 21105111
12. Somatostatin analogues for treatment of polycystic liver disease. Gevers TJ, Drenth JP, Curr Opin Gastroenterol 2011 27 294 300 10.1097/MOG. 0b013e328343433f 21191289
13. Somatostatin analogues reduce liver volume in polycystic liver disease. van Keimpema L, de Man RA, Drenth JP, Gut 2008 57 1338 9 10.1136/gut.2008.155721 18719151
14. Effect of octreotide on polycystic liver volume. van Keimpema L, Drenth JP, Liver Int 2010 30 633 4 10.1111/j.1478-3231.2009.02123.x 19744163
15. Intermediate Volume on Computed Tomography Imaging Defines a Fibrotic Compartment that Predicts Glomerular Filtration Rate Decline in Autosomal Dominant Polycystic Kidney Disease Patients. Caroli A, Antiga L, Conti S, Sonzogni A, Fasolini G, Ondei P, et al. Am J Pathol 2011 179 619 27 10.1016/j.ajpath.2011.04.036 21683674
16. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Meijer E, Boertien WE, Nauta FL, Bakker SJ, van Oeveren W, Rook M, et al. Am J Kidney Dis 2010 56 883 95 10.1053/j.ajkd.2010.06.023 20888104
17. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Pavik I, Jaeger P, Kistler AD, Poster D, Krauer F, Cavelti-Weder C, et al. Kidney Int 2011 79 234 40 10.1038/ki.2010.375 20944552
18. Adult polycystic liver disease: is fenestration the most adequate operation for long-term management? Gigot JF, Jadoul P, Que F, Van Beers BE, Etienne J, Horsmans Y, et al. Ann Surg 1997 225 286 94 10.1097/00000658- 199703000-00008 9060585 (Pubitemid 27131565)
19. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM, Lancet 1994 343 824 7 10.1016/S0140-6736(94)92026-5 7908078 (Pubitemid 24147512)
20. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, Ann Intern Med 1999 130 461 70 10075613 (Pubitemid 29135798)
21. Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report. Antiga L, Piccinelli M, Fasolini G, Ene-Iordache B, Ondei P, Bruno S, et al. Clin J Am Soc Nephrol 2006 1 754 60 10.2215/CJN.02251205 17699283
22. 2011 http://www.euroqol.org Ref Type: Internet communication
23. Evaluation of a gastrointestinal symptoms questionnaire. Bovenschen HJ, Janssen MJ, van Oijen MG, Laheij RJ, van Rossum LG, Jansen JB, Dig Dis Sci 2006 51 1509 15 10.1007/s10620-006-9120-6 16927133 (Pubitemid 44379291)
24. A threshold selection method from gray-level histogram. Otsu N, IEEE Trans Syst Man Cybern 1979 9 5
25. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, et al. Kidney Int 2005 68 206 16 10.1111/j.1523-1755.2005.00395.x 15954910 (Pubitemid 43181378)